Report from the Amino Acids Working Group Ann Bowron Anny Brown - - PowerPoint PPT Presentation

report from the amino acids working group
SMART_READER_LITE
LIVE PREVIEW

Report from the Amino Acids Working Group Ann Bowron Anny Brown - - PowerPoint PPT Presentation

Report from the Amino Acids Working Group Ann Bowron Anny Brown Helena Kemp Introduction Helena Kemp Southmead Hospital, Bristol Where are we now? Variation in current practice Where should we be going? Is there a need to


slide-1
SLIDE 1

Report from the Amino Acids Working Group

Ann Bowron Anny Brown Helena Kemp

slide-2
SLIDE 2

Introduction

Helena Kemp Southmead Hospital, Bristol

slide-3
SLIDE 3

Where are we now?

  • Variation in current practice
slide-4
SLIDE 4

Where should we be going?

  • Is there a need to change/standardise current practice?
  • If so - what areas need to be addressed?
  • If so – is there a need to develop Metbionet guidelines?
slide-5
SLIDE 5

Existing Guidelines

  • Amino acid workshop report

– 38th Annual Symposium of the SSIEM - Cambridge 2000 – Mayne, Roche & Deverell (2001). JIMD 24: 305-308.

  • ERNDIM

– Recommendations to improve the quality of diagnostic quantitative analysis of amino acids in plasma and urine using cation exchange liquid chromatography with post column ninhydrin reaction and detection. (May 2002)

  • American college of Medical Genetics (ACMG)

– Standards and guidelines for Clinical Genetics Labs (Biochemical Genetics – Guidelines for amino acid analysis (updated 2003)

slide-6
SLIDE 6

Working Group - membership

  • Participation by all Stakeholder laboratories invited
  • Representation from 5 laboratories

– Sheffield Children’s Hospital – Claire Hart – Dublin Children’s Hospital – Dierdre Deverell – Birmingham Children’s Hospital – Mary Anne Preece – North Bristol NHS Trust – Helena Kemp, Anny Brown – United Bristol Hospitals Trust – Ann Bowron

slide-7
SLIDE 7

Working group - Aims

  • ‘To collect information to guide the development
  • f recommendations for the provision of a

comprehensive, appropriately organised, specialist amino acid diagnostic and monitoring service’.

slide-8
SLIDE 8

Work streams

  • Repertoire

– Primary amino acid disorders – Other conditions – Nutrition

  • Analytical methods present and future
  • Clinical indications

– Requesting patterns and practices

  • Requirements for monitoring IMD
  • International views
slide-9
SLIDE 9

Afternoon Session

  • CSF amino acid analysis
  • Amino acids reporting

– UKNEQAS amino acids cognitive scheme – Clinical Biochemists view – The Dietician’s experience – The requesting doctor

slide-10
SLIDE 10

Amino Acid Analysis – What do we need to do?

Ann Bowron, Bristol Royal Infirmary Anny Brown, Southmead Hospital

slide-11
SLIDE 11

Amino Acid Analyser

  • Expensive
  • Time-consuming
  • Interferences (esp urine)
  • Increased number of requests
  • Demands on staff + budget
slide-12
SLIDE 12

Amino Acid Analyser

  • Can quantitate > 60 compounds
  • Sigma standard 37 amino acids
slide-13
SLIDE 13
  • Why are we using this technology
  • What are we trying to achieve?
  • Which amino acids do we need to

measure to achieve this?

slide-14
SLIDE 14

Why do we measure amino acids?

  • Metabolic screen

– To exclude/diagnose AA disorder

  • Information about other diseases
  • Assessment of nutritional status
  • Monitor treatment
slide-15
SLIDE 15
  • 1. Metabolic Screen
  • List of amino acid disorders
  • How are they diagnosed?
slide-16
SLIDE 16
  • Spreadsheet of findings (this will be

given as a handout)

slide-17
SLIDE 17

Established AA disorders

Glutamine Glutamine Citrulline Citrulline Arginine Arginine Argininosuccinic Argininosuccinic acid acid Ornithine Ornithine Valine Valine Leucine Leucine Isoleucine Isoleucine Allo Allo-

  • isoleucine

Phenylalanine Phenylalanine Tyrosine Tyrosine Methionine Methionine Cystine Cystine Taurine Taurine Sulphocysteine Sulphocysteine Serine Serine Glycine Glycine Lysine Lysine 18 amino acids isoleucine 18 amino acids

slide-18
SLIDE 18

Evidence is unclear

Homocystine Sarcosine Carnosine Homocarnosine Anserine B-alanine B-AIBA Histidine Tryptophan aAAA OH-lysine Saccharopine Proline OH-proline cystathionine

slide-19
SLIDE 19
  • Few cases described
  • Same findings in well siblings
  • Conditions are ?benign
  • Some described before modern

methods used

  • ?no recent cases as not in routine

standards

slide-20
SLIDE 20
  • 2. Amino Acids in other

disease states

  • Spreadsheet – handout
slide-21
SLIDE 21
  • 3. Assessment of

nutrition status

slide-22
SLIDE 22

Amino acids & Nutrition

  • From diet
  • Continuous exchange between structural

muscle protein and free aa’s in blood

  • Plasma aa levels influenced by timing of

meals & their calorie and protein content.

  • Muscle proteolysis probably triggered by

lowering insulin levels and relate to calorie deprivation.

slide-23
SLIDE 23

Dietary requirements

  • Mature adult

– Protein turnover 300g/day – ~ 40g/day lost, must be replaced – RDA ~ 56g/day

  • Growth, pregnancy & convalescence

– Need extra protein

  • Inadequate intake difficult to

diagnose unless severe and prolonged

slide-24
SLIDE 24

Total calorie vs isocaloric protein deprivation

  • Key aas; glycine, alanine & BCAAs
  • Isocaloric protein deprivation

– BCAA ↓ (particularly valine) – Alanine ↑, Glycine ↑

  • Total calorie deprivation (starvation)

– BCAA ↑ – Alanine ↓, Glycine ↓

slide-25
SLIDE 25

Use of aa ratios

  • Indicator of muscle breakdown
  • Monitor patients on restricted diets

– Increase dietary protein indicated – Proteolysis may stress liver in UCD – Val chronically low in PA

  • ? Patients very sensitive to protein

deprivation

slide-26
SLIDE 26

Ratiogram

Proc 1st International Conf Amino Acids, Vienna, 1989

slide-27
SLIDE 27

Interpretation

  • Timing of sample - IMPORTANT
  • What control data are we using?

– Fasting levels / 8 hours – 4 hrs post-meal – ? Protein ingested

  • Interpretation with care!
slide-28
SLIDE 28

Conclusion

  • Current methods may not be

sustainable

  • Number of AAs routinely measured

can be reduced

  • ? Alternative methods
  • ? Other AAs as second line tests
slide-29
SLIDE 29

Obstacles

  • Lack of evidence for some amino acid

disorders

  • Resistance to change
  • Specific requirements for individual

labs